Back to Press Releases

An Exciting New Face for StriVectin®: A Modern Website for a Science-Based Skincare Brand

Created for today’s sophisticated beauty consumer, the new site blends modern design with streamlined functionality

StriVectin Logo 432C_BLACK-01.jpg

Nashville, Tenn. October 7, 2025 - Revance is proud to announce that its StriVectin® premium skincare brand, a leader in advanced skincare solutions, has launched its newly redesigned website, offering a modern look and superior user experience.

The new design delivers a modern, streamlined interface that makes it easier than ever to explore StriVectin’s award-winning product portfolio, discover ingredient and skincare education, and shop seamlessly for a connected consumer journey. The experience reflects StriVectin’s clinical credibility, highlighting its science-backed heritage through infographics, badges, and content that reinforce its positioning. Updated navigation, enhanced product pages, and curated content aim to guide visitors to the right solutions for their skin concerns, all while providing an engaging brand experience.

“Our customers look to StriVectin not only for science-backed formulas that work, but also for trusted guidance on their skincare journey,” said Sumita Butani, Senior Vice President, Skincare. “The redesigned site was intentionally crafted for our sophisticated consumer base who seeks proven, clinical results. Through expanded storytelling, we’re bringing to life StriVectin’s rich history, our authority in skin science, and our mission to educate, creating a true destination for both loyal users and new prospects. This investment underscores our commitment to innovation and connection, ensuring that every interaction with StriVectin reflects the excellence our community expects.”

Key features of the redesigned website include:

● Streamlined Navigation: Clear product categories and skin concern filters for a faster shopping experience. Products are thoughtfully organized by benefits and concerns, such as fine lines or loss of firmness, and product type, helping customers quickly identify the right offerings.

● Enhanced Shopping Tools: Richer product detail pages, customer reviews, and recommendations tailored to individual needs. A new interactive Skin Consultation guides users to the right solutions with ease, helping them personalize their regimen.

● Educational Content: Robust resources on ingredients, skin science, and product usage to empower informed skincare decisions. The site also highlights and educates on StriVectin’s proprietary technologies, including NIA-114®, the foundational ingredient of every formula, and innovative peptides like Alpha-3 Peptide®.

● Engaging Brand Storytelling: Expanded content brings to life StriVectin’s history, dedication to skin science, and mission to educate, positioning the site as a destination for both loyal users and new prospects.

● Continuous Innovation: This relaunch marks the beginning of an ongoing digital evolution, with StriVectin committed to testing, learning, and optimizing site features to deepen engagement while driving growth.

The redesigned site extends the brand’s mission to deliver smarter, science-driven skincare beyond the jar. The new website is now live at www.strivectin.com.

About StriVectin

StriVectin is an award-winning, premium skincare brand backed by over 35 years of clinical research. Fueled by its mission to empower you at every stage of your skincare journey, StriVectin delivers advanced, targeted formulas for aging skin's most challenging concerns. As innovators in skin science, all StriVectin formulas feature our NIA-114® technology. This powerhouse molecule, even more effective than Niacinamide, has been clinically proven to strengthen the skin barrier, helping skin look and act younger. Our results are real, visible, and validated by independent clinical studies on every product - it's how we built a winning portfolio. StriVectin is cruelty-free, paraben-free, and suitable for all skin types.

StriVectin products are available through top department stores and specialty retailers across North America, Europe, the Middle East, and Asia. For more details, visit strivectin.com.

About Revance

Revance is a fast-growing, highly acquisitive, global aesthetics and skincare company committed to delivering innovative aesthetics and market-leading skincare solutions across every stage of life. With a differentiated portfolio and market position, Revance meets the evolving needs of patients and consumers worldwide through continued innovation and the commercialization of new products and treatments. Focused on skin science for life, Revance continues to expand its global footprint, with distribution spanning 60 countries and a significant opportunity to enter new markets.

Revance's balanced portfolio includes innovative products in the aesthetics space such as DAXXIFY® (daxibotulinumtoxinA-lanm) for injection, the RHA® Collection of dermal fillers by Teoxane SA, and SkinPen®, an industry-leading microneedling device. RHA® technology is proprietary to and manufactured in Switzerland by Teoxane SA, and Revance is an independent distributor of Teoxane SA to supply the RHA Collection of dermal fillers to the U.S. market. In addition, its consumer skincare portfolio includes leading brands such as PanOxyl®, Blue Lizard®, StriVectin® and BIOJUVE®.

RHA® is a trademark of TEOXANE SA.

Learn more at Revance.com, RevanceAesthetics.com, CrownLaboratories.com, and CrownAesthetics.com. Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.

IMPORTANT SAFETY INFORMATION for DAXXIFY® (daxibotulinumtoxinA-Ianm) for injection

Indications

(daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients and for the treatment of cervical dystonia in adults.

WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.

IMPORTANT SAFETY INFORMATION

Contraindications

DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).

Warnings and Precautions

Please refer to Boxed Warning for Distant Spread of Toxin Effect.

The potency Units of DAXXIFY® are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.

Adverse Reactions

The most commonly observed adverse reactions are:

Glabellar lines (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%).

Cervical Dystonia (≥5%): headache (9%), injection site pain (8%), injection site erythema (6%), muscular weakness (5%), and upper respiratory tract infection (5%).

Drug Interactions

Co-administration of DAXXIFY® and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY® may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown.

Use in Specific Populations

DAXXIFY® is not recommended for use in children or pregnant women.

Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.

To report side effects associated with DAXXIFY®, please visit safety.revance.com, or call 1-877-373-8669. You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch

DAXI-004726

Facebook Instagram Twitter LinkedIn

FOR CUSTOMER SERVICE, PRODUCT INFORMATION, NEW ACCOUNTS OR ADVERSE EVENTS CALL: 877-3REV-NOW

1222 DEMONBREUN ST

20TH FLOOR

NASHVILLE, TN 37203

©2025 REVANCE.
RHA® and RHA Redensity® are registered trademarks of TEOXANE SA, manufactured in Switzerland. The TEOXANE RHA® Collection is exclusively distributed by Revance®. All other trademarks are the property of their respective owners.
CORP-00147

SOCIAL MEDIA COMMUNITY GUIDELINES PRIVACY POLICY TERMS OF USE
WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.